These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 21047593)

  • 1. Lead-time in the European Randomised Study of Screening for Prostate Cancer.
    Finne P; Fallah M; Hakama M; Ciatto S; Hugosson J; de Koning H; Moss S; Nelen V; Auvinen A
    Eur J Cancer; 2010 Nov; 46(17):3102-8. PubMed ID: 21047593
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Detection of prostate cancer: the impact of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Schröder FH
    Can J Urol; 2005 Feb; 12 Suppl 1():2-6; discussion 92-3. PubMed ID: 15780157
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?
    Barry MJ; Mulley AJ
    J Natl Cancer Inst; 2009 Mar; 101(6):362-3. PubMed ID: 19276451
    [No Abstract]   [Full Text] [Related]  

  • 4. Detection rates of cancer, high grade PIN and atypical lesions suspicious for cancer in the European Randomized Study of Screening for Prostate Cancer.
    Laurila M; van der Kwast T; Bubendorf L; di Lollo S; Pihl CG; Ciatto S; Hugosson J; Määttänen L; Roobol MJ; Kujala PM
    Eur J Cancer; 2010 Nov; 46(17):3068-72. PubMed ID: 21047588
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSA levels and cancer detection rate by centre in the European Randomized Study of Screening for Prostate Cancer.
    Otto SJ; Moss SM; Määttänen L; Roobol M; Zappa M; Nelen V; Kwiatkowski M; Villers A; Hugosson J; Sanchez AB; de Koning HJ
    Eur J Cancer; 2010 Nov; 46(17):3053-60. PubMed ID: 21047586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Epilogue: different approaches for prostate cancer screening in the EU?
    Schröder FH; Denis L; Roobol MJ
    Eur J Cancer; 2010 Nov; 46(17):3120-5. PubMed ID: 21047595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
    Telesca D; Etzioni R; Gulati R
    Biometrics; 2008 Mar; 64(1):10-9. PubMed ID: 17501937
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.
    Ito K; Yamamoto T; Miyakubo M; Takechi H; Ohi M; Shibata Y; Suzuki K
    J Urol; 2007 Oct; 178(4 Pt 1):1258-63; discussion 1263-4. PubMed ID: 17698107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Summaries for patients. Screening smarter, not harder, for prostate cancer.
    Ann Intern Med; 2013 Feb; 158(3):I-30. PubMed ID: 23381056
    [No Abstract]   [Full Text] [Related]  

  • 10. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
    Roobol MJ; Grenabo A; Schröder FH; Hugosson J
    J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prostate-specific antigen testing and prostate cancer screening.
    Djavan B; Eckersberger E; Finkelstein J; Sadri H; Taneja SS; Lepor H
    Prim Care; 2010 Sep; 37(3):441-59, vii. PubMed ID: 20705192
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of insignificant prostate cancer using free/total PSA: results of a case-finding protocol on 14,453 patients.
    Pepe P; Aragona F
    Prostate Cancer Prostatic Dis; 2010 Dec; 13(4):316-9. PubMed ID: 20714341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of prostate-specific antigen testing on familial prostate cancer risk estimates.
    Bratt O; Garmo H; Adolfsson J; Bill-Axelson A; Holmberg L; Lambe M; Stattin P
    J Natl Cancer Inst; 2010 Sep; 102(17):1336-43. PubMed ID: 20724726
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate-specific antigen tests and prostate cancer screening: an update for primary care physicians.
    Kell JS
    Can J Urol; 2010 Feb; 17 Suppl 1():18-25. PubMed ID: 20170597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Should prostate-specific antigen screening be offered to asymptomatic men?
    van Vugt HA; Bangma CH; Roobol MJ
    Expert Rev Anticancer Ther; 2010 Jul; 10(7):1043-53. PubMed ID: 20645694
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical value of prostate specific antigen screening in early detection of prostate cancer].
    Hua LX; Qiao D; Song NH; Feng NH; Yang J; Zhang JX; Chen JG; Zhang W; Sui YG; Wu HF
    Zhonghua Zhong Liu Za Zhi; 2009 Sep; 31(9):705-9. PubMed ID: 20021870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Updated Japanese Urological Association Guidelines on prostate-specific antigen-based screening for prostate cancer in 2010.
    ;
    Int J Urol; 2010 Oct; 17(10):830-8. PubMed ID: 20825509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Critical appraisal of prostate-specific antigen in prostate cancer screening: 20 years later.
    Pienta KJ
    Urology; 2009 May; 73(5 Suppl):S11-20. PubMed ID: 19375622
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
    Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
    Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening for prostate cancer: current recommendations.
    Wilson SS; Crawford ED
    Urol Clin North Am; 2004 May; 31(2):219-26. PubMed ID: 15123402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.